{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:03:34Z","timestamp":1791497014615,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PATH Foundation"},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.03.038","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T01:17:58Z","timestamp":1490318278000},"page":"5455-5462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes"],"prefix":"10.1016","volume":"35","author":[{"given":"Rama Devudu","family":"Puligedda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kouiavskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fetweh H.","family":"Al-Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana Devi","family":"Kattala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Yaqoob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Sandeep","family":"Bhagavathula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Dessain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.038_b0005","unstructured":"GPEI. Polio eradication and endgame strategic plan, 2013\u20132018; 2013."},{"key":"10.1016\/j.vaccine.2017.03.038_b0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/rmv.401","article-title":"Polio eradication: the OPV paradox","volume":"13","author":"Dowdle","year":"2003","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0015","first-page":"358","article-title":"Update on vaccine-derived polioviruses detected worldwide, April 2011\u2013June 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.03.038_b0020","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1128\/JVI.79.20.12623-12634.2005","article-title":"Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0025","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1086\/379791","article-title":"Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis","volume":"188","author":"Khetsuriani","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.038_b0030","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/JVI.79.2.1062-1070.2005","article-title":"Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine","volume":"79","author":"Cherkasova","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0035","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/JVI.00277-16","article-title":"A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged sabin 2 vaccine poliovirus","volume":"90","author":"Korotkova","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0040","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2013.18.38.20586","article-title":"Insidious reintroduction of wild poliovirus into Israel, 2013","volume":"18","author":"Anis","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.03.038_b0045","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/infdis\/jit831","article-title":"Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after Mexican national immunization weeks","volume":"209","author":"Troy","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.038_b0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.vaccine.2015.01.018","article-title":"Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication","volume":"33","author":"Guo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.038_b0055","series-title":"Exploring the role of antiviral drugs in the eradication of polio: workshop report","author":"Council","year":"2006"},{"key":"10.1016\/j.vaccine.2017.03.038_b0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","article-title":"Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.038_b0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00705-010-0778-x","article-title":"100 years poliovirus: from discovery to eradication. A meeting report","volume":"155","author":"Skern","year":"2010","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.1954.02950010023009","article-title":"Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases","volume":"156","author":"Hammon","year":"1954","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2017.03.038_b0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3851\/IMP1838","article-title":"Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073","volume":"16","author":"Kouiavskaia","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.vaccine.2017.03.038_b0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2014.05.005","article-title":"Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains","volume":"108","author":"Puligedda","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.03.038_b0085","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/JVI.02553-10","article-title":"Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis","volume":"85","author":"Chen","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2015.01.023","article-title":"A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses","volume":"65","author":"Kouiavskaia","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1073\/pnas.97.1.73","article-title":"Three-dimensional structure of poliovirus receptor bound to poliovirus","volume":"97","author":"Belnap","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.038_b0100","doi-asserted-by":"crossref","first-page":"20242","DOI":"10.1073\/pnas.1320041110","article-title":"Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor","volume":"110","author":"Chen","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.038_b0105","doi-asserted-by":"crossref","first-page":"e17491","DOI":"10.1371\/journal.pone.0017491","article-title":"Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein","volume":"6","author":"Adekar","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.038_b0110","doi-asserted-by":"crossref","first-page":"12889","DOI":"10.1073\/pnas.1323502111","article-title":"Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010","volume":"111","author":"Drexler","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.038_b0115","series-title":"Manual for the virological investigation of polio","author":"World Health Organization","year":"1997"},{"key":"10.1016\/j.vaccine.2017.03.038_b0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e3182a9b3f1","article-title":"Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women","volume":"65","author":"Atrio","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2017.03.038_b0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-4682-11-30","article-title":"Comparative analysis of human and mouse immunoglobulin variable heavy regions from IMGT\/LIGM-DB with IMGT\/HighV-QUEST","volume":"11","author":"Shi","year":"2014","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.vaccine.2017.03.038_b0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S002217240003936X","article-title":"The measurement of the D-antigen in poliovirus preparations","volume":"60","author":"Beale","year":"1962","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2017.03.038_b0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.038_b0140","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1586\/14760584.2015.1052800","article-title":"Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame","volume":"14","author":"Parker","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.038_b0145","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit671","article-title":"Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination","author":"Wright","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.038_b0150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature12442","article-title":"Cross-neutralization of four paramyxoviruses by a human monoclonal antibody","volume":"501","author":"Corti","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.03.038_b0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.03.038_b0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coi.2016.05.013","article-title":"Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies","volume":"42","author":"Wu","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-032712-095916","article-title":"Broadly neutralizing antiviral antibodies","volume":"31","author":"Corti","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2012.10.004","article-title":"Broadly neutralizing antibodies against HIV-1: templates for a vaccine","volume":"435","author":"van Gils","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.03.038_b0175","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural basis for Marburg virus neutralization by a cross-reactive human antibody","volume":"160","author":"Hashiguchi","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.03.038_b0180","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.4049\/jimmunol.1401054","article-title":"Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1","volume":"193","author":"Chaudhury","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.038_b0185","doi-asserted-by":"crossref","first-page":"763","DOI":"10.15585\/mmwr.mm6530a3","article-title":"Update on vaccine-derived polioviruses \u2013 worldwide, January 2015\u2013May 2016","volume":"65","author":"Jorba","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.03.038_b0190","first-page":"1031","article-title":"Possible eradication of wild poliovirus type 3 \u2013 worldwide, 2012","volume":"63","author":"Kew","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.03.038_b0195","unstructured":"Chen Z, Purcell RH, Chumakov K. Compositions and methods for treating poliovirus; 2012. Patent WO2012112842."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T08:20:46Z","timestamp":1535962846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":39,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17303547"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}